[Frontiers in Bioscience S3, 919-928, June 1, 2011]

Histopathology and outcome of acute humoral rejection in renal allografts

Anjali A. Satoskar1, Ronald Pelletier2 , Gyongyi M. Nadasdy1, Mitchell Henry 2, Ronald Ferguson2, Tibor Nadasdy1

1Departments of Pathology, The Ohio State University Medical Center, Columbus, OH 43210,2Department of Surgery and Comprehensive Transplant Center, The Ohio State University Medical Center, Columbus, OH 43210

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Method
3.1. Biopsy Selection
3.2. Patient Groups and Subgroups
3.3. Biopsy Evaluation
3.4. Histology and C4d immunostaining
3.5. Serologic detection of anti-HLA antibodies
3.6. Induction and maintenance immunosuppression therapy
3.7. Anti-rejection therapy
3.8. Statistical Analysis
4. Results
4.1. Histologic features and graft outcome
4.2. Demographics
4.3. Serum creatine at 2 years in functioning grafts
4.4. Proportion of graft loss
4.5. Post-transplant panel reactive antibody (PRA) titers
5. Discussion
6. References

1. ABSTRACT

Our purpose was to see if histopathologic features of acute antibody-mediated rejection (AMR) in renal allografts have prognostic value; and to compare two-year graft survival with and without additional therapy with plasmapheresis and intravenous immunoglobulin (IVIG). We reviewed renal allograft biopsies taken within the first 6 months after transplant from patients with C4d positive AMR, performed between January 2000 to December 2005 (n=57). We formed two groups: Group 1: biopsied between 2003 and 2005 (n=26), when C4d staining was routinely performed and option for plasmapheresis and IVIG was available; Group 2: biopsied between 2000 and 2002 (n=31), retrospectively found to be C4d positive. Patients whose biopsies showed cortical necrosis or arterial fibrinoid necrosis had early graft loss. Other histopathologic features did not statistically correlate with graft loss. Overall, additional plasmapheresis/IVIG treatment did not show convincing improvement in graft survival or function at 2 years post-transplant, but all six patients with thrombotic microangiopathy (TMA) who received plasmapheresis/IVIG had functioning grafts at two-year follow-up.